By Dean Seal
Shares of Altamira Therapeutics rose after the company reported more positive results from a trial of its Bentrio nasal spray.
The stock was up 9.4% at 33 cents in early trading. Shares have fallen 96% over the past 12 months.
The company said Thursday morning that additional data from the clinical trial evaluating Bentrio as a treatment for seasonal allergies confirms its efficacy in managing seasonal allergic rhinitis symptoms.
Altamira previously reported that the trial met its primary efficacy endpoint, and said Thursday that it has also met a secondary endpoint of improving nasal symptoms.
Write to Dean Seal at email@example.com
Read the full article here